{"id":"W4306926620","doi":"10.1016/j.ygyno.2022.08.021","title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Genentech; National Institutes of Health; PharmaMar; Seagen; NRG Oncology; Ipsen; Clovis Oncology; Gateway Foundation; Eisai; National Comprehensive Cancer Network; Regeneron Pharmaceuticals; Mersana Therapeutics; Shire; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; PARP inhibitor; Loss of heterozygosity; Placebo; Randomized controlled trial; Polymerase; Pathology; Gene; Genetics; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000256121,0.000194395,0.0008206252,0.00007482941,0.0001527547,0.000005084022,0.0001130783,0.000209007,0.001031247],"category_scores_gemma":[0.0002044447,0.0001767148,0.0001510756,0.00008454749,0.0003103247,0.00002534098,0.0001022868,0.000215169,0.000003634018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006771315,"about_ca_system_score_gemma":0.000338849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001166777,"about_ca_topic_score_gemma":0.00002808789,"domain_scores_codex":[0.99814,0.0002059327,0.0006906678,0.0004774655,0.0001812145,0.0003047019],"domain_scores_gemma":[0.9981637,0.0008463821,0.000419091,0.0002709743,0.0001610657,0.0001388111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003719647,0.003657984,0.9242523,0.00003340691,0.0004354936,0.0001373192,0.0004401092,0.00002018227,0.005722274,0.006940955,0.001856476,0.0527839],"study_design_scores_gemma":[0.01588806,0.01167719,0.9427657,0.000009875225,0.0001900348,0.00001538734,0.0001076824,0.0001321793,0.0007143487,0.00691916,0.02142103,0.0001593948],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929323,0.0001128665,0.0009135223,0.002534247,0.0009521755,0.00108681,0.001245313,0.00002730464,0.0001955157],"genre_scores_gemma":[0.9891598,0.0001298131,0.00564689,0.002947605,0.0001756869,0.0008411815,0.0009342426,0.00002227426,0.0001425716],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05262451,"threshold_uncertainty_score":0.9998819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0388994921237036,"score_gpt":0.3305733788332055,"score_spread":0.291673886709502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}